Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Evgen enters MoU with University of Dundee to advance SFX-01 towards trial for NASH

Dec. 5, 2019

Phase II trial of CNSA-001 in PKU meets primary and secondary endpoints

Dec. 4, 2019

Novo Nordisk patents melanocortin MC4 receptor agonists

Dec. 3, 2019

New cholesterol target works independently of LDL receptor

Dec. 3, 2019

Pharmacodynamic responses seen with RNA interference therapy ARO-ANG3 in healthy volunteers

Dec. 2, 2019

New prostanoid EP3 receptor antagonists synthesized at Bayer

Dec. 2, 2019

MiR-125b as a novel target in diabetes

Dec. 2, 2019

The enteropeptidase inhibitor SCO-792 enters phase II development

Nov. 29, 2019

DP-13 begins phase II trial in primary aldosteronism

Nov. 29, 2019

iRNA therapy ARO-APOC3 reduces triglycerides in healthy volunteers

Nov. 28, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...